DCLK1 and neoplasm: In HCT116 (colon) and AsPC-1 (pancreatic) tumor xenografts, DCLK1 siRNA nanoparticle treatment significantly reduces tumor growth and inhibits pluripotency and angiogenic factors without any indication of toxicity[14,15].